bluebird bio (NASDAQ: BLUE) reported Q2 EPS of ($3.58), $0.39 worse than the analyst estimate of ($3.19). Revenue for the quarter came in at $7.47 million versus the consensus estimate of $19.68 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.